What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.”In the company’s words, NCT04057898 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis
- Main trialPhase 2/3
- “A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.”In the company’s words, NCT04057898 on ClinicalTrials.gov
- Other names
- MN-166
Other drugs for Amyotrophic Lateral Sclerosis
Coming up1
- Apr 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | Apr 2027 | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | |
| Phase 2Completed | Aug 2017 | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 2Completed | 30 Jun 2022 | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | |
| Phase 1/2Completed | 31 Dec 2019 | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | |
| Phase 1/2Completed | 7 Aug 2023 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026